EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't
PubMed
25687109
DOI
10.1177/2047487315569401
PII: 2047487315569401
Knihovny.cz E-resources
- Keywords
- EUROASPIRE, cardiovascular prevention, guidelines, rehabilitation,
- MeSH
- Time Factors MeSH
- Risk Reduction Behavior * MeSH
- Exercise MeSH
- Diet adverse effects MeSH
- Guideline Adherence MeSH
- Adult MeSH
- Risk Assessment MeSH
- Cardiology trends MeSH
- Cardiovascular Agents therapeutic use MeSH
- Comorbidity MeSH
- Coronary Disease diagnosis epidemiology therapy MeSH
- Smoking adverse effects MeSH
- Practice Patterns, Physicians' trends MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Smoking Cessation MeSH
- Prevalence MeSH
- Prospective Studies MeSH
- Cross-Sectional Studies MeSH
- Health Care Surveys MeSH
- Risk Factors MeSH
- Sedentary Behavior MeSH
- Secondary Prevention trends MeSH
- Aged MeSH
- Practice Guidelines as Topic MeSH
- Societies, Medical * MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe epidemiology MeSH
- Names of Substances
- Cardiovascular Agents MeSH
AIMS: To determine whether the Joint European Societies guidelines on cardiovascular prevention are being followed in everyday clinical practice of secondary prevention and to describe the lifestyle, risk factor and therapeutic management of coronary patients across Europe. METHODS AND RESULTS: EUROASPIRE IV was a cross-sectional study undertaken at 78 centres from 24 European countries. Patients <80 years with coronary disease who had coronary artery bypass graft, percutaneous coronary intervention or an acute coronary syndrome were identified from hospital records and interviewed and examined ≥ 6 months later. A total of 16,426 medical records were reviewed and 7998 patients (24.4% females) interviewed. At interview, 16.0% of patients smoked cigarettes, and 48.6% of those smoking at the time of the event were persistent smokers. Little or no physical activity was reported by 59.9%; 37.6% were obese (BMI ≥ 30 kg/m(2)) and 58.2% centrally obese (waist circumference ≥ 102 cm in men or ≥88 cm in women); 42.7% had blood pressure ≥ 140/90 mmHg (≥140/80 in people with diabetes); 80.5% had low-density lipoprotein cholesterol ≥ 1.8 mmol/l and 26.8% reported having diabetes. Cardioprotective medication was: anti-platelets 93.8%; beta-blockers 82.6%; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 75.1%; and statins 85.7%. Of the patients 50.7% were advised to participate in a cardiac rehabilitation programme and 81.3% of those advised attended at least one-half of the sessions. CONCLUSION: A large majority of coronary patients do not achieve the guideline standards for secondary prevention with high prevalences of persistent smoking, unhealthy diets, physical inactivity and consequently most patients are overweight or obese with a high prevalence of diabetes. Risk factor control is inadequate despite high reported use of medications and there are large variations in secondary prevention practice between centres. Less than one-half of the coronary patients access cardiac prevention and rehabilitation programmes. All coronary and vascular patients require a modern preventive cardiology programme, appropriately adapted to medical and cultural settings in each country, to achieve healthier lifestyles, better risk factor control and adherence with cardioprotective medications.
Cardiac Rehabilitation Unit Cardiology Department Hospital Universitario La Paz Madrid Spain
Cardiology Unit Department of Medicine Solna Karolinska Institutet Stockholm Sweden
Comprehensive Heart Failure Centre and Department of Medicine 1 University of Würzburg Germany
Department of Cardiology National Heart Hospital Sofia Bulgaria
Department of Cardiology Shupyk's National Medical Academy of Postgraduate Education Kiev Ukraine
Department of Heart Failure and Valve Disease Skåne University Hospital Lund Sweden
Institut Pasteur de Lille Université de Lille France
Kuopio University Hospital Finland
The Adelaide and Meath Hospital Dublin Ireland
The European Society of Cardiology Sophia Antipolis Cedex France Hacettepe University Ankara Turkey
References provided by Crossref.org
Secondary Prevention after Myocardial Infarction: What to Do and Where to Do It
